NTLA

Intellia is a pre-commercial clinical-stage biotech, and the financials read exactly like one: FY2025 revenue of just $67.7M (all collaboration revenue, +16.9% YoY) against a $413M net loss and a $395M operating cash burn. The P/S of 29x is meaningless here — this is not valued on sales but on the option value of two in vivo CRISPR programs. Margins (operating -651.7%, net -609.9%) and ROE of -61.5% are not signals of a broken business but of a company spending $389M on R&D to push lonvo-z (HAE) and nex-z (ATTR amyloidosis) through Phase 3. Per the MD&A, these are 'the first in vivo genome editing product candidates into Phase 3 development,' and management is 'preparing for the planned commercial launch of lonvo-z in the first half of 2027.' That single line is the entire thesis: the stock is a bet on durable, single-infusion gene editing reaching market.

The balance sheet is the reassuring part. Liabilities/equity is a low 0.25x, equity is $671M, current assets ($528M) cover current liabilities ($104M) five times over, and there is no meaningful debt load — so the risk is dilution, not insolvency. But the runway math is the worry: cash & equivalents of just $155M against a ~$395M annual burn means the company is leaning on its broader marketable-securities/investment position (total assets $842M) and will almost certainly need to raise before or around the 2027 launch. The 14.1% YoY rise in share count to 118M shows dilution is already underway and accumulated deficit has reached -$2.59B. Encouragingly, FY2025 operating loss actually narrowed (R&D fell $77M to $389M, op loss improved $93M), suggesting some spending discipline as programs mature.